A phase I study of MLN4924 and belinostat in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome is a research paper published in Cancer Chemotherapy and Pharmacology (2025). On theSindex it has a DataRank of 0.533. It has been cited 16 times, with 16 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.425
From this paper's citation signal
Citation Network Contribution
0.108
From 12 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 16 citers.
NIH-NCI Cancer Center Support Grant
Grant: P30 CA016059
NIH: ETCTN
Grant: UM1CA186644
NIH
Grant: P30CA006973
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Shared Instrument Grant
Grant: S10OD020091
National Center for Advancing Translational Sciences
Grant: UL1TR003098
Leukemia and Lymphoma Society
Grant: R6508-18
NCI NIH HHS
Grant: U24 CA247648
NCI NIH HHS
Grant: UM1 CA186691
Winn Career Development Award
MeSH Terms
Keywords